Drug colossus Pfizer has a sprawling research and development segment.Within its two R&D divisions,PharmaTherapeutics and BioTherapeutics,the company is investigating treatments for a host of ailments.The research units in each of the divisions include Allergy and Respiratory;Antibacterials;Biocorrection;Cardiovascular Metabolic&Endocrine Diseases;Genitourinary;Inflammation and Immunology;Neuroscience;Oncology;Pain;Tissue Repair;and Vaccine Research.PharmaTherapeutics is concerned with small molecule therapies,while BioTherapeutics handles large molecule therapies.
Pfizer recently closed on its acquisition of rival Wyeth and is busy integrating the two firms' research and development activities.This will result in the shuttering of six facilities and some 2,000 layoffs.Facilities to be closed are located in New York,North Carolina,New Jersey and the U.K.The company is headquartered in New York City,under CEO Jeff Kindler.
No comments:
Post a Comment